0001213900-18-014204.txt : 20181022 0001213900-18-014204.hdr.sgml : 20181022 20181022131205 ACCESSION NUMBER: 0001213900-18-014204 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20181022 DATE AS OF CHANGE: 20181022 EFFECTIVENESS DATE: 20181022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RELMADA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001553643 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455401931 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-324029 FILM NUMBER: 181132018 BUSINESS ADDRESS: STREET 1: 750 THIRD AVENUE, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-547-9591 MAIL ADDRESS: STREET 1: 750 THIRD AVENUE, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: CAMP NINE, INC. DATE OF NAME CHANGE: 20120706 D 1 primary_doc.xml X0708 D LIVE 0001553643 RELMADA THERAPEUTICS, INC. 750 THIRD AVENUE, 9TH FLOOR NEW YORK NY NEW YORK 10017 212-547-9591 NEVADA None CAMP NINE, INC. Corporation true Sergio Traversa 750 Third Avenue 9th Floor New York NY NEW YORK 10017 Executive Officer Director Paul Kelly 750 Third Avenue 9th Floor New York NY NEW YORK 10017 Director Maged Shenouda 750 Third Avenue 9th Floor New York NY NEW YORK 10017 Director Ottavio Vitolo 750 Third Avenue 9th Floor New York NY NEW YORK 10017 Executive Officer Biotechnology No Revenues 06b false 2018-10-12 false true true false 10000 Alexander Capital, LP 40077 None None 17 STATE STREET 5TH FLOOR NEW YORK NY NEW YORK 10004 CO COLORADO CT CONNECTICUT FL FLORIDA GA GEORGIA MA MASSACHUSETTS NV NEVADA NJ NEW JERSEY NY NEW YORK OR OREGON PA PENNSYLVANIA RI RHODE ISLAND SC SOUTH CAROLINA TX TEXAS false 10000000 3279998 6720002 false 30 280000 0 Not included in the sales commission amount is a non-accountable 1% allowance ($28,000) for expenses paid to the agent. The agent also received warrants to purchase 303,333 shares of common stock of the issuer and a $20,000 upfront due diligence fee. 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false RELMADA THERAPEUTICS, INC. /s/ Sergio Traversa Sergio Traversa CEO 2018-10-22